Extensive and Rapid Diagnostic Assay for Herpesviral Infections in
the Central Nervous System>
Extensive and Rapid Diagnostic Assay for Herpesviral Infections in the Central Nervous System
(Thomson Reuters ONE) - Mobidiag's CE-IVD-marked Prove-it(TM) Herpes-test helps the clinicianin targeting antiviral treatment correctly for patients with severeherpesviral infectionsHelsinki, Finland - June 2, 2009 - Finnish biotech company Mobidiagannounces CE-marked herpesvirus microarray for rapid In VitroDiagnostics (IVD) of life-threatening central nervous systeminfections. The achieved certificate ensures the safety of theproduct in clinical use and opens European markets for the company.Prove-it(TM) Herpes identifies seven herpesviruses in a single assay,whereas most current methods search for only one virus at a time, orare unable to identify all viruses covered by Mobidiag's assay.Human herpesviruses cause life-threatening infections in the centralnervous system such as encephalitis, the inflammation of the brain.The European estimated prevalence of central nervous systeminfections caused by herpesviruses is close to a million a year.Thus, the annual market size for herpesviral diagnostics is 100million euros in Europe alone."Due to the diverse symptoms of herpesviral infections, the clinicianfaces a great challenge in either confirming or ruling out theinfection based on clinical examination alone", said JaakkoPellosniemi, CEO of Mobidiag. "Rapid diagnostics is vital. Leftuntreated, the mortality in encephalitis can be as high as 50%.Prove-it(TM) Herpes provides rapid and reliable results enablingcorrect targeting of antiviral treatment", Pellosniemi continued.The clinical performance and safety of Prove-it(TM) Herpes wasevaluated at six University, hospital or private laboratories aroundEurope. The results of analyzing 525 cerebrospinal fluid samples inparallel with the current DNA-based methods were excellent:sensitivity 90% and specificity 98%. Prove-it(TM) Herpes demonstratedadditional value by identifying 14 multi-infections and 17 HumanHerpesvirus 7 infections missed or not covered by the currentdiagnostics. Furthermore, Mobidiag's test found twenty infections notsuspected by the clinician at all."No longer the clinician needs to know which virus test to choose -Prove-it(TM) Herpes answers all questions at once. Furthermore, thecoverage of the assay eliminates the need for multiple tests andthereby saves time and can halve the diagnostics costs in hospitals",Pellosniemi said.Prove-it(TM) Herpes was developed in co-operation with the HospitalDistricts of Helsinki and Uusimaa and the University of Helsinki,Finland.Contact:CEO Jaakko Pellosniemi, Mobidiag Ltd, tel.358405011004,jaakko.pellosniemi[a]mobidiag.comMobidiag is a Finnish biotechnology company developing, producing andmarketing rapid diagnostic tests for hospital laboratories. Thecompany focuses on diagnostics of serious infections with DNA-tests.www.mobidiag.comThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="ReadSoft signs US$250,000 deal with U.S. government organization>
">
" alt="Mandatory notification of trade>
">
Datum: 02.07.2009 - 05:00 Uhr
Sprache: Deutsch
News-ID 1002238
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Extensive and Rapid Diagnostic Assay for Herpesviral Infections in
the Central Nervous System>
"
steht unter der journalistisch-redaktionellen Verantwortung von
Mobidiag Oy (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
